| Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure. | |
| | |
MedLine Citation:
|
PMID: 19125264 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: The aim of this study is to compare the effect of ethinyl estradiol 0.03 mg/gestodene 0.075 mg (EE/GSD) with ethinylestradiol 0.03 mg/drospirenone 3 mg (EE/DRSP) administered according to conventional 21/7 regimen on body mass index (BMI), blood pressure (BP), lipid metabolism and hemostatic parameters. METHOD: In this study, 160 healthy women were randomized to EE/GSD mg or EE/DRSP for 12 months. Mean differences in BMI, high density lipoprotein-cholesterol (HDL-C) and low density lipoprotein-cholesterol (LDL-C), total cholesterol (TC) levels and BP compared to baseline were assessed. RESULTS: One hundred and forty-five (89%) of the women completed all 12 treatment cycles. The subjects randomly assigned into two treatment groups. Group EE/GSD (n = 71) and group EE/DRSP (n = 72). In group B, BMI values were significantly lower than baseline at the sixth cycle. DRSP/EE had more favorable effects on BP than GSD/EE with the mean systolic and diastolic BPs remaining lower in the DRSP/EE group. The difference between the two preparations was not statistically significant at the end of the study. TC levels remained similar in both groups throughout the study period. In both groups LDL-C levels decreased, triglyceride and HDL-C levels significantly increased from baseline levels. These changes result in increasing HDL-C/LDL-C ratio, demonstrating anti-atherogenic effect. Menstrual cycle patterns and the incidence of adverse events were similar between groups. The duration of withdrawal bleeding decreased during the study for both groups and was similar. CONCLUSION: The EE/DRSP regimen provides good cycle control with reliable contraceptive efficacy and low incidence of adverse events. Compared with the EE/GSD preparation, the EE/DRSP preparation demonstrated a more favorable effect on BMI and BP with the mean BMI and mean BP remaining lower than baseline mean. The new formulation may be especially beneficial for women susceptible to body weight gain and rise in BP. |
| | |
Authors:
|
Recep Yildizhan; Begum Yildizhan; Ertan Adali; Pinar Yoruk; Fatih Birol; Necdet Suer |
Related Documents
:
|
18629374 - Lipid-lowering effects of methanolic extract of vernonia amygdalina leaves in rats fed ... 15999954 - Nightmares and serum cholesterol level: a preliminary report. 7517834 - Gender-related response to fluvastatin in patients with heterozygous familial hyperchol... 1454844 - The calorically restricted low-fat nutrient-dense diet in biosphere 2 significantly low... 10996354 - Alterations in the main steps of reverse cholesterol transport in male patients with pr... 22231784 - Liver patt1 deficiency protects male mice from age-associated but not high-fat diet-ind... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Randomized Controlled Trial Date: 2009-01-06 |
Journal Detail:
|
Title: Archives of gynecology and obstetrics Volume: 280 ISSN: 1432-0711 ISO Abbreviation: Arch. Gynecol. Obstet. Publication Date: 2009 Aug |
Date Detail:
|
Created Date: 2009-06-26 Completed Date: 2009-09-24 Revised Date: 2009-10-31 |
Medline Journal Info:
|
Nlm Unique ID: 8710213 Medline TA: Arch Gynecol Obstet Country: Germany |
Other Details:
|
Languages: eng Pagination: 255-61 Citation Subset: IM |
Affiliation:
|
Department of Obstetric and Gynecology, School of Medicine, Yuzuncu Yil University, Van, Turkey. recepyildizhan@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Androstenes / pharmacology* Blood Pressure / drug effects* Body Mass Index Contraceptives, Oral, Combined / pharmacology* Estrogens / pharmacology Ethinyl Estradiol / pharmacology Female Humans Lipid Metabolism / drug effects* Lipids / blood Norpregnenes / pharmacology* Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Androstenes; 0/Contraceptives, Oral, Combined; 0/Estrogens; 0/Lipids; 0/Norpregnenes; 57-63-6/Ethinyl Estradiol; 60282-87-3/Gestodene; 67392-87-4/drospirenone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prenatal management of an allantoic cyst with patent urachus.
Next Document: Accessory breast tissue presenting as a vulvar mass in an adolescent girl.